Top

Published in:

01-04-2009 | Epidemiology

Time-varying pattern of recurrence risk for Chinese breast cancer patients

Authors: Wenjin Yin, Genhong Di, Liheng Zhou, Jinsong Lu, Guangyu Liu, Jiong Wu, Kunwei Shen, Qixia Han, Zhenzhou Shen, Zhimin Shao

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Abstract

Purpose To analyze the rule of recurrence risk for breast cancer patients after surgery in order to get characteristics for Chinese breast cancer. Methods We performed a retrospective study of 2,213 female unilateral breast cancer patients undergoing surgery in Cancer hospital of Fudan University, Shanghai, China. Survival curves were performed with Kaplan–Meier method and annual recurrence hazard was estimated by hazard function. Results Annual recurrence hazard curve for entire population showed a double-peaked pattern, with a first major recurrence surge reaching the maximum at the second year after surgery and a second recurrence peak near the 9.5th year. The analysis according to tumor size, axillary lymph node (ALN) status (T1 + T2 versus T3, node-positive versus node-negative) and menopausal status as well as hormone receptor (HR) status proved that the double-peaked pattern was present in each subgroup. Compared with ER-positive tumors, ER-negative breast cancers were more likely to recur early. As far as Her-2/neu status was concerned, Her-2/neu-positive patients exhibited a relatively pronounced and variable pattern and tended to have more relapse across all time periods (P < 0.05). Conclusions The double-peaked pattern observed in our patients gives further support to tumor dormancy hypothesis. It contributes to different treatment strategies (e.g. the type and timing of adjuvant therapy) for different patients, which provide the possibility to improve survival.

Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66PubMedCrossRef

Weiss RB, Woolf SH, Demakos E et al (2003) Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol 21:1825–1835PubMedCrossRef

Kimura M, Yanagita Y, Fujisawa T et al (2007) Study of time-course changes in annual recurrence rates for breast cancer: data analysis of 2,209 patients for 10 years post-surgery. Breast Cancer Res Treat 106:407–411PubMedCrossRef

Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746PubMed

Brackstone M, Townson JL, Chambers AF (2007) Tumour dormancy in breast cancer: an update. Breast Cancer Res 9:208PubMedCrossRef

Simes RJ, Zelen M (1985) Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator’s primer. J Clin Oncol 3:1418–1431PubMed

Karrison TG, Ferguson DJ, Meier P (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91:80–85PubMedCrossRef

Gasparini G, Biganzoli E, Bonoldi E et al (2001) Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Res Treat 65:71–75PubMedCrossRef

Demicheli R, Abbattista A, Miceli R et al (1996) Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 41:177–185PubMedCrossRef

10.

Demicheli R, Miceli R, Valagussa P et al (2000) Re: dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 92:347–348PubMedCrossRef

11.

Demicheli R, Bonadonna G, Valagussa P et al (2005) Comment to Jatoi et al. report. Breast Cancer Res Treat 93:1–2

12.

Yakovlev AY, Tsodikov AD, Boucher K et al (1999) The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer 85:1789–1798PubMedCrossRef

13.

Jatoi I, Tsimelzon A, Weiss H et al (2005) Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 89:173–178PubMedCrossRef

14.

Baum M, Demicheli R, Hrushesky W et al (2005) Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer 41:508–515PubMedCrossRef

15.

Demicheli R, Miceli R, Brambilla C et al (1999) Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’. Breast Cancer Res Treat 53:209–215PubMedCrossRef

16.

Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271PubMedCrossRef

17.

Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144PubMedCrossRef

18.

Demicheli R, Miceli R, Moliterni A et al (2005) Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 16:1449–1457PubMedCrossRef

19.

Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846PubMedCrossRef

20.

McShane LM, Altman DG, Sauerbrei W et al (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRef

21.

Tamoxifen, Arimidex, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, Buzdar A et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53PubMedCrossRef

22.

Demicheli R (2001) Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol 11:297–306PubMedCrossRef

23.

Demicheli R, Retsky MW, Swartzendruber DE et al (1997) Proposal for a new model of breast cancer metastatic development. Ann Oncol 8:1075–1080PubMedCrossRef

24.

Hilsenbeck SG, Ravdin PM, de Moor CA et al (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227–237PubMedCrossRef

25.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef

26.

Peto R, Davies C, on Behalf of the ATLAS Collaboration (2007) ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women – preliminary results. Paper presented at the 30th annual San Antonio breast cancer symposium, Henry B. Gonzalez Convention Center, San Antonio, Texas, USA, 13–16 December 2007

27.

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRef

28.

Gusterson BA, Gelber RD, Goldhirsch A et al (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049–1056PubMed

29.

Bull SB, Ozcelik H, Pinnaduwage D et al (2004) The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 22:86–96PubMedCrossRef

30.

Slamon D, Eiermann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Paper presented at the 28th San Antonio breast cancer symposium, Henry B. Gonzalez Convention Center, San Antonio, Texas, USA, 8–11 December 2005

31.

Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36PubMedCrossRef

32.

Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRef

33.

Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820PubMedCrossRef

34.

Slamon D, Eiermann W, Robert N et al (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Paper presented at the 29th San Antonio breast cancer symposium, Henry B. Gonzalez Convention Center, San Antonio, Texas, USA, 14–17 December 2006

35.

Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261PubMed

Title: Time-varying pattern of recurrence risk for Chinese breast cancer patients
Authors: Wenjin Yin
Genhong Di
Liheng Zhou
Jinsong Lu
Guangyu Liu
Jiong Wu
Kunwei Shen
Qixia Han
Zhenzhou Shen
Zhimin Shao
Publication date: 01-04-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0022-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective

Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

Analysis of the progression of intraductal proliferative lesions in the breast by PCR-based clonal assay

A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women

Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history

Keynote webinar | Spotlight on antibody–drug conjugates in cancer